Drug
ND-L02-s0201
Status:
Phase 2
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Intravenous (IV) Injection
Funder Type:
Industry
Drug Details
ND-L02-s0201 is an oligonucleotide drug using HSP47 (Heat Shock Protein 47) siRNA, which moderates collagen synthesis and secretion that causes fibrosis.
Study Purpose
This phase 2 clinical study will be a randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.